Shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) were up 5.3% during trading on Thursday . The company traded as high as $18.44 and last traded at $18.38, with a volume of 62,633 shares changing hands. The stock had previously closed at $17.45.

A number of analysts have recently commented on LJPC shares. Lake Street Capital started coverage on shares of La Jolla Pharmaceutical in a report on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price on the stock. SunTrust Banks Inc. started coverage on shares of La Jolla Pharmaceutical in a report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Finally, Jefferies Group restated a “buy” rating on shares of La Jolla Pharmaceutical in a report on Wednesday, June 8th. Seven research analysts have rated the stock with a buy rating, La Jolla Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $38.83.

The stock’s market cap is $315.13 million. The stock has a 50-day moving average price of $16.86 and a 200 day moving average price of $17.61.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.09. On average, equities analysts expect that La Jolla Pharmaceutical Co. will post ($3.80) earnings per share for the current year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.